Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231932 · ClinicalTrials.gov registry record
Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors
A clinical trial, sponsored by National Institute of Nursing Research (NINR).
- Terminated
- Registry status
- 163
- Enrollment target
NCT01231932: Clinical Trial study, sponsored by National Institute of Nursing Research (NINR).
NCT01231932 is a clinical trial that was terminated before completion, run by National Institute of Nursing Research (NINR). The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01231932 was terminated before completion, sponsored by National Institute of Nursing Research (NINR).
- TERMINATED
- Registry status
- 163 participants
- Enrollment target
Study Summary
Background: \- Fatigue is a common side effect of cancer and its treatment. Up to 96% of patients with cancer have fatigue. The cause of fatigue in people with cancer or those receiving treatment is poorly understood, making fatigue hard to treat. More research is necessary to understand why cancer patients experience fatigue. Previous research has shown that fatigue may be caused by a number of factors, including problems with the immune system response of the body while undergoing cancer treatment. The researchers of this study are trying to understand how the immune system and other chemicals of the body change while a person receives cancer treatment and how these changes play a role in causing fatigue. The researchers are also interested in how a person s quality of life is affected by fatigue. Objectives: \- To study fatigue in individuals who have cancer, are receiving cancer treatment, or have completed cancer treatment. Eligibility: * Individuals at least 18 years of age. * Receiving cancer treatment, OR completed primary treatment for cancer (e.g., cancer survivors), OR on active surveillance for localized cancer. Design: * This study involves an initial screening visit and up to three outpatient visits. * Participants will be screened with a medical history review (can be done virtually) and blood tests. A physical exam might also occur. * Participants undergoing cancer treatment that has a clear completion date, will have the following visits: * Before the start of treatment. * At the end of treatment. * At least 3 months after treatment ends. * Participants not receiving treatment, are cancer survivors, or undergoing cancer treatment that does not have a clear completion date, will have up to 3 visits: * Before the start of treatment or whenever you begin the study. * At least 3 months after your first visit. * At least 3 months after your second visit. * At each study visit, participants will complete the following tasks (some of t
Primary Outcome
Self-reported fatigue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2011-02-04 |
| Est. Completion | 2025-04-16 |
Why NCT01231932 stopped before completion
NCT01231932 is an observational study that tracks outcomes without assigning an intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01231932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01231932 about?
NCT01231932 is a clinical study titled "Characterizing Fatigue Experienced by Cancer Patients Receiving Primary Treatment and Cancer Survivors". Background: \- Fatigue is a common side effect of cancer and its treatment. Up to 96% of patients with cancer have fatigue. The cause of fatigue in people with cancer or those receiving treatment is poorly understood, making fatigue hard to treat. More research is necessary to understand why cancer...
What is the current status of trial NCT01231932?
This trial is currently terminated. The enrollment target is 163 participants. The study started on 2011-02-04. Estimated completion is 2025-04-16.
Who is sponsoring clinical trial NCT01231932?
This trial is sponsored by National Institute of Nursing Research (NINR), which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI